ChromaVision develops test for aggressive cancers
This article was originally published in Clinica
ChromaVision Medical Systems is developing a test for assessing the aggressiveness of cancer based on its Automated Cellular Imaging System. In a collaboration with the University of Southern California, Kenneth Norris Jr Comprehensive Cancer Center, the company plans to develop an objective tumour angiogenesis test that evaluates the density of new blood vessels, which enable tumour growth. The new test could help identify patients who have particularly aggressive cancers and who may benefit from new anti-angiogenesis drugs currently under development, said the San Juan Capistrano, California-based company.
You may also be interested in...
ASTM International is proposing a new standard that will provide a cleaning agent formula for removing dried blood from stainless steel medical devices.
Executive appointments at MyoKardia, Scancell Holdings and Sutro Biopharma
The merger between Mylan and Pfizer’s Upjohn unit finally concluded on 16 November 2020, giving Viatris the go ahead for business. The newly-established company has announced receiving tentative approval for its 10mg pediatric dolutegravir tablets from the FDA under the PEPFAR program.